L2P4 (TFA)

L2P4 TFA is a peptide-based and EBNA1 targeting fluorescent probe, which inhibits the EBNA1 homodimer formation and selectively inhibits EBV+ tumor growth. L2P4 TFA exhibits cytotoxicity in EBV-positive C666-1 cell with LC50 of 46.4 μM[1].

Product Specifications

UNSPSC

12352209

Target

EBV; Peptide-Drug Conjugates (PDCs)

Related Pathways

Antibody-drug Conjugate/ADC Related; Anti-infection

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.25

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCSC)C(N[C@@H](C(C)C)C(N[C@@H](CC2=CC=CC=C2)C(NCC(NCC(N[C@@H](CCCNC(N)=N)C(N[C@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@@H](NC(CCCCCNC([C@@H](NC(C[N+]3=CC=C(/C=C/C(C=C4)=CC=C4N(CC)CC)C=C3)=O)CS)=O)=O)CC5=CC=C(O)C=C5.OC(C(F)(F)F)=O.[Cl-].[x]

Molecular Formula

C93H138ClN25O16S2.xC2HF3O2

Molecular Weight

1961.83 (free base)

References & Citations

[1]Li X, et al., Biocompatible Porphyrin-Peptide Conjugates as Theranostic Agents Targeting the Epstein-Barr Virus. Chempluschem. 2022 Aug 10;87 (11) :e202200184.